SCHEMBL22728458

SCHEMBL22728458

Cc1ccc(-c2csc(NC(=O)c3cocn3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.61
LMNA P02545 5/20 0.61
KDM4E B2RXH2 3/20 0.61
HTT P42858 2/20 0.61
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
ALDH1A1 P00352 3/20 0.60
POLB P06746 2/20 0.60
ESR1 P03372 1/20 0.60
ESR2 Q92731 1/20 0.60
HSD17B10 Q99714 1/20 0.60
NPC1 O15118 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
RAB9A P51151 3/20 0.59
THRB P10828 1/20 0.56
GSTO1 P78417 1/20 0.56
CSNK2A2 P19784 1/20 0.52
CSNK2B P67870 1/20 0.52
CSNK2A1 P68400 1/20 0.52
CSNK2A3 Q8NEV1 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22728481 0.83 LMNA (0.64) MAPTLMNAKDM4EHTTMEN1
SCHEMBL12248896 0.81 ADORA3 (0.68) MAPTLMNAKDM4EHTTMEN1
SCHEMBL22728560 0.81 MEN1 (0.62) MAPTLMNAKDM4EHTTMEN1
SCHEMBL26884109 0.80 LMNA (0.58) MAPTLMNAKDM4EHTTMEN1
SCHEMBL22728498 0.80 LMNA (0.78) MAPTLMNAKDM4EHTTMEN1
SCHEMBL22728454 0.80 MAPT (0.62) MAPTLMNAKDM4EHTTMEN1
SCHEMBL22728558 0.80 MPL (0.69) MAPTLMNAKDM4EHTTMEN1
SCHEMBL235190 0.79 KDM4E (0.70) MAPTLMNAKDM4EHTTMEN1
SCHEMBL26884355 0.79 KMT2A (0.66) MAPTLMNAKDM4EHTTMEN1
SCHEMBL22728476 0.78 LMNA (0.65) MAPTLMNAKDM4EHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF CARTHRONIX INC (US) 2023-11-30 US disclosed
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2022-08-23 US disclosed
WO-2022082071-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF US THEREOF CARTHRONIX, INC. (US) 2022-04-21 WO disclosed
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2022-02-17 US disclosed
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER UNIVERSITY OF SOUTHERN CALIFORNIA 2020-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382903-A1 SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF STAT1, STAT3, STAT6 MAPT 4065/4885LMNA 4496/4885KDM4E 4225/4885
US-11420964-B2 Compositions and methods for modulating inflammatory and degenerative disorder TNF, MSR1, GRN MAPT 2213/4885LMNA 1893/4885KDM4E 4725/4885
US-20220048901-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MAPT 2213/4885LMNA 1893/4885KDM4E 4725/4885
US-20200377494-A1 COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY AND DEGENERATIVE DISORDER TNF, MSR1, GRN MAPT 2213/4885LMNA 1893/4885KDM4E 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.